NA
TCRR

NewEdge Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

NewEdge Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-47
Closed -$47 – 4306
2022
Q4 		$47 Buy
+47
New +$63 ﹤0.01% 3484

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NewEdge Advisors's TCRR Position: Q1 2023 in Review

NewEdge Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2023, closing a stake of 47 shares — an estimated $47 sold.

NewEdge Advisors first reported a position in TCRR in Q4 2022 and held it in 1 quarter. The position peaked at $47 in Q4 2022. 59 funds tracked by Wall St. Rank hold TCRR as of Q1 2023.

  • NewEdge Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • NewEdge Advisors sold 47 TCR2 Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $47.
  • NewEdge Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • NewEdge Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $47 in Q4 2022.
  • 59 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.